GAMMAGARD LIQUID Dosing and Administration
for PI and MMN
When starting a patient on treatment with GAMMAGARD LIQUID, the correct dose and rate of administration is based on the treatment indication and the individual patient’s weight.1
Intravenous immune globulin (IVIG) administration is available for patients with primary immunodeficiency (PI), multifocal motor neuropathy (MMN). Additionally, a subcutaneous IG (SCIG) option is also available for patients with PI.1
See PI dosing calculator
Dose and infusion rates for PI1
Dose and infusion rates for PI1
| IV Administration | SC Administration | |
|---|---|---|
| Dose | 300 to 600 mg/kg every 3 to 4 weeks based on clinical response |
Initial dose is 1.37 x previous IV dose divided by number of weeks between IV doses
Maintenance dose is based on clinical response and target IgG trough level |
| Initial Rate of Infusion | 0.5 mL/kg/hr (0.8 mg/kg min) for 30 minutes |
40 kg BW and greater: 30 mL/site at 20 mL/hr/site
Under 40 kg BW: 20 mL/site at 15 mL/hr/site |
| Maintenance Infusion Rate | Increase every 30 minutes (if tolerated) up to 5 mL/kg/hr (8 mg/kg/min) |
40 kg BW and greater: 30 mL/site at 20 to 30 mL/hr/site
Under 40 kg BW: 20 mL/site at 15 to 20 mL/hr/site |
| IV Administration | |
|---|---|
| Dose | 300 to 600 mg/kg every 3 to 4 weeks based on clinical response |
|
Initial Rate of Infusion |
0.5 mL/kg/hr (0.8 mg/kg min) for 30 minutes |
|
Maintenance Infusion Rate |
Increase every 30 minutes(if tolerated) up to 5 mL/kg/hr(8 mg/kg/min) |
| SC Administration | |
|---|---|
| Dose | Initial dose is 1.37 X previous intravenous dose Maintenance dose is based on clinical response and target IgG trough level |
|
Initial Rate of Infusion |
40 kg BW and greater: 30 mL/site at 20 mL/hr/site Under 40 kg BW: 20 mL/site at 15 mL/hr/site |
|
Maintenance Infusion Rate |
40 kg BW and greater: 30 mL/site at 20 to 30 mL/hr/site Under 40 kg BW: 20 mL/site at 15 to 20 mL/hr/site |
BW = body weight.
Adjust dose according to IgG levels and clinical response, as the frequency and dose of IG may vary from patient to patient.
See MMN dosing calculator
Dose and infusion rates for MMN1
Dose and infusion rates for MMN1
| IV Administration | |
|---|---|
| Dose | Dose range 0.5 to 2.4 grams/kg/month based on clinical response |
| Initial Rate of Infusion | 0.5 mL/kg/hr (0.8 mg/kg/min) |
| Maintenance Infusion Rate | Infusion rate may be increased if tolerated up to 5.4 mL/kg/hr (9 mg/kg/min) |
IVIG dosing for PI1
Increase every 30 minutes (if tolerated) up to 5 mL/kg/hr (8 mg/kg/min)
- Initial infusion rate is 0.5 mL/kg/hr for 30 minutes
- It is important to individualize rates for each patient based on clinical response and tolerability
- Patients beginning treatment or switching from one IVIG product to another should be started at the lower infusion rates, and rates should be gradually increased as tolerated
IVIG dosing for MMN1
The dose of GAMMAGARD LIQUID may need to be adjusted to achieve the desired clinical response. In the clinical study for MMN treatment, the dose ranged from 0.5 to 2.4 g/kg/mo.
While receiving GAMMAGARD LIQUID, 9% of patients in the clinical study experienced neurological decompensation that required an increase in dose. Accordingly, dose adjustment may be necessary in order to avoid worsening of muscle weakness in patients with MMN.
Dosing calculator
Dosing range
Calculated infusion rates†
300 to 600 mg/kg (0.3 to 0.6 g/kg) every 3 or 4 weeks based on clinical response
500 to 2400 mg/kg (0.5 to 2.4 g/kg) per month based on clinical response
Dosing range
300 to 600 mg/kg (0.3 to 0.6 g/kg) every 3 or 4 weeks based on clinical response
| Min(g) | 15 |
| Max(g) | 30 |
Calculated infusion rates†
300 to 600 mg/kg (0.3 to 0.6 g/kg) every 3 or 4 weeks based on clinical response
| Time |
0 hr - 0.5 hr |
0.5 hr - 1 hr |
1 hr - 1.5 hrs |
1.5 hrs - 2 hrs |
2 hrs - 2.5 hrs |
2.5 hrs - end of infusion |
| mL/hr | 25 | 50 | 100 | 150 | 200 | 250 |
Dosing range
500 to 2400 mg/kg (0.5 to 2.4 g/kg) per month based on clinical response
| Min(g) | 25 |
| Max(g) | 120 |
Calculated infusion rates†
500 to 2400 mg/kg (0.5 to 2.4 g/kg) per month based on clinical response
| Time |
0 hr - 0.5 hr |
0.5 hr - 1 hr |
1 hr - 1.5 hr |
1.5 hr - 2 hrs |
2 hrs - 2.5 hrs |
2.5 hrs - 3 hrs |
3 hrs - end of infusion |
| mL/hr | 25 | 50 | 100 | 150 | 200 | 250 | 270 |
*Weights have been rounded to the nearest pound; calculations based on this have also been rounded.
†GAMMAGARD LIQUID IV maintenance infusion rate may be increased every 30 minutes based on patient tolerability.
SCIG dosing for PI
Prior to switching patients from GAMMAGARD LIQUID IVIG to SCIG, obtain the serum IgG trough level to guide subsequent dosing. To calculate the target trough IG level for SCIG treatment, add 281 mg/dL to the IG trough level obtained after the last IV treatment. Start the initial SCIG dose approximately 1 week after the last IVIG infusion.1
To guide dose adjustment, calculate the difference between the patient’s target serum IgG trough level and the actual IgG trough level during SCIG treatment1:
Change in weekly dose of GAMMAGARD LIQUID for intended IgG trough level adjustment1a
| Body Weight | 100 mg/dL | 200 mg/dL | 300 mg/dL | 400 mg/dL |
|---|---|---|---|---|
| 10 kg | 2 mL | 4 mL | 6 mL | 8 mL |
| 20 kg | 4 mL | 8 mL | 11 mL | 15 mL |
| 30 kg | 6 mL | 11 mL | 17 mL | 23 mL |
| 40 kg | 8 mL | 15 mL | 23 mL | 30 mL |
| 50 kg | 9 mL | 19 mL | 28 mL | 38 mL |
| 60 kg | 11 mL | 23 mL | 34 mL | 45 mL |
| 70 kg | 13 mL | 26 mL | 40 mL | 53 mL |
| 80 kg | 15 mL | 30 mL | 45 mL | 60 mL |
| 90 kg | 17 mL | 34 mL | 51 mL | 68 mL |
| 100 kg | 19 mL | 38 mL | 57 mL | 75 mL |
| 110 kg | 21 mL | 42 mL | 62 mL | 83 mL |
| 120 kg | 23 mL | 45 mL | 68 mL | 91 mL |
| 130 kg | 25 mL | 49 mL | 74 mL | 98 mL |
| 140 kg | 26 mL | 53 mL | 79 mL | 106 mL |
aDerived using a linear approximation to the nomogram method with a slope of 5.3 kg/dL.
Additional considerations
Ensure patients with preexisting renal insufficiency are not volume depleted; discontinue GAMMAGARD LIQUID if renal function deteriorates.1
For patients over 65 years of age or judged to be at risk for renal dysfunction or thrombotic events, administer GAMMAGARD LIQUID at the minimum infusion rate practicable.1
Continue reviewing safety information
There are known patient risk factors to consider with IVIG products, including GAMMAGARD LIQUID. Review important safety information, including contraindications and specific warnings and precautions to take when prescribing and monitoring patients treated with GAMMAGARD LIQUID.
For patients with PI, GAMMAGARD LIQUID IV is given by a healthcare professional. It can be administered at1:
- A patient’s home
- A physician’s office
- A hospital
- An infusion center
SC administration may be given by the patient or a caregiver, after they’ve been properly trained by a healthcare professional.
Looking for MMN dosing information?
Additional considerations
Ensure patients with preexisting renal insufficiency are not volume depleted; discontinue GAMMAGARD LIQUID if renal function deteriorates.1
For patients over 65 years of age or judged to be at risk for renal dysfunction or thrombotic events, administer GAMMAGARD LIQUID at the minimum infusion rate practicable.1
Continue reviewing safety information
There are known patient risk factors to consider with IVIG products, including GAMMAGARD LIQUID. Review important safety information, including contraindications and specific warnings and precautions to take when prescribing and monitoring patients treated with GAMMAGARD LIQUID.
For patients with MMN, GAMMAGARD LIQUID IV is given by a healthcare professional. It can be administered at:1:
- A patient’s home
- A physician’s office
- A hospital
- An infusion center
Looking for PI dosing information?
Designed with ease of use in mind
GAMMAGARD LIQUID is available in 6 vial sizes, which can offer flexibility based on individual patient dosage, and help to reduce waste.1
See vial sizes
